Consider buying shares of OmniAb (OABI) to capture significant long-term royalty upside tied to its high-potential drug candidate partnership with Johnson & Johnson. Take advantage of recent pullbacks in cloud infrastructure by dip-buying Microsoft (MSFT) and Oracle (ORCL) for an attractive rebound opportunity. Position for downside in SELLAS Life Sciences Group (SLS) ahead of its upcoming 80th clinical milestone readout, where expert sentiment indicates a low 25% probability of trial success. Target Cerebras Systems for a short-term mean-reversion trade to capitalize on an overextended 14% to 18% price surge that lacked a fundamental catalyst. Prepare to short SanDisk on signs of technical exhaustion, as the broader memory cycle appears near its peak and risks future supply saturation.

OmniAb (OABI)

• Martin expressed a strong bullish stance on the stock and mentioned buying shares.
• The investment thesis centers around OmniAb's royalty on a Johnson & Johnson drug candidate, which Martin believes could potentially become one of the biggest drugs in the world.

Takeaways

• Consider a long position in OABI driven by long-term royalty upside from high-profile pharmaceutical partnerships.

SanDisk (Western Digital / Flash Memory)

• Flash and memory stocks experienced strong upside momentum, with SanDisk rallying 8% to 9% during the session.
• Martin is actively short SanDisk, viewing the trade as crowded and believing the current memory cycle is peaking.
• The analyst day highlighted the high scalability of flash storage, which Martin views negatively as an indicator of future supply saturation and margin compression.

Takeaways

• Monitor SanDisk for potential downside reversals if the current memory rally runs out of momentum, keeping in mind the risk of fighting strong short-term upward price action.

Taiwan Semiconductor Manufacturing Company (TSM)

• Discussion highlighted TSMC's manufacturing node mix: 3nm accounts for roughly 25% of business, 5nm accounts for about 35%, and 2nm is beginning commercial rollout.
• Demand remains surprisingly resilient across older legacy nodes, with 65nm sales up 50%.
• Martin discussed political risks around domestic vs. foreign semiconductor production, noting potential policy pressure under Trump to force chip designers to onshore production.

Takeaways

• TSM remains fundamentally dominant across leading and trailing edge nodes, but investors should weigh potential geopolitical and U.S. tariff/manufacturing policy risks.

Cerebras Systems

• Cerebras experienced heavy upward momentum during the trading session, surging between 14% and 18% with no specific news catalyst.
• Martin opened a short position against the stock, viewing the intraday price spike as disconnected from immediate fundamentals.

Takeaways

• High intraday volatility makes Cerebras a candidate for mean-reversion short trades, though timing momentum spikes carries elevated risk.

SELLAS Life Sciences Group (SLS)

• Martin maintains a short position in SLS.
• The company is approaching its anticipated 80th clinical event milestone for its lead asset.
• Physician and expert feedback reportedly gave the drug a low probability of clinical success (approximately 25% or lower).

Takeaways

• High-risk clinical catalyst ahead; potential downside risk for SLS if upcoming clinical trial data fails to meet efficacy endpoints.

Amylyx Pharmaceuticals (AMLX)

• The company is preparing to release clinical trial data for its GLP-1 antagonist candidate targeting post-bariatric hypoglycemia (PBH) in a 78-patient study.
• Martin expressed skepticism regarding whether the trial will meet its primary composite endpoint, suggesting positive outcomes may already be priced into the company's ~$3 billion valuation.

Takeaways

• Exercise caution heading into the binary clinical trial readout, as meeting the primary endpoint remains statistically challenging in this patient population.

Enterprise AI & Cloud Infrastructure (NVDA, AMD, ORCL, MSFT)

• NVIDIA (NVDA): GPU lifecycle debate was analyzed; older generations (such as A100s) continue to see active data center usage even as newer Blackwell and Rubin architectures roll out.
• Advanced Micro Devices (AMD): Traded actively on rumors concerning Google TPU design wins and taking market share from competitors like Marvell.
• Oracle (ORCL) & Microsoft (MSFT): Explored as potential dip-buying or bounce opportunities following short-term weakness across large-cap software and cloud infrastructure.

Takeaways

• High demand for AI compute capacity supports hardware longevity for NVDA, while large-cap pullbacks in ORCL and MSFT present potential entry points for bounce trades.

GameStop (GME)

• Martin remains fundamentally bearish on GameStop, describing the underlying retail business model as weak.
• Skepticism was expressed regarding Chairman Ryan Cohen's ability or incentive to drive a major acquisition (e.g., rumors involving eBay) to reshape the company.

Takeaways

• Avoid long-term fundamental investment in GME, as turnaround prospects through large-scale M&A appear unlikely.